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N-acetylcysteine (NAC) was found to improve transplantation-free survival in only those adults with
nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy (HE).
Because non-APAPALF differs significantly between children and adults, the Pediatric Acute Liver Fail-
ure (PALF) Study Group evaluated NAC in non-APAP PALF. Children from birth through age 17
years with non-APAPALF enrolled in the PALF registry were eligible to enter an adaptively allocated,
doubly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/
day in 5% dextrose in water [D5W]) or placebo (D5W) for up to 7 days. The primary outcome was
1-year survival. Secondary outcomes included liver transplantation-free survival, liver transplantation
(LTx), length of intensive care unit (ICU) and hospital stays, organ system failure, and maximum HE
score. A total of 184 participants were enrolled in the trial with 92 in each arm. The 1-year survival did
not differ significantly (P5 0.19) between the NAC (73%) and placebo (82%) treatment groups. The
1-year LTx-free survival was significantly lower (P 5 0.03) in those who received NAC (35%) than
those who received placebo (53%), particularly, but not significantly so, among those less than 2 years
old with HE grade 0-1 (NAC 25%; placebo 60%; P5 0.0493). There were no significant differences
between treatment arms for hospital or ICU length of stay, organ systems failing, or highest recorded
grade of HE. Conclusion: NAC did not improve 1-year survival in non-APAP PALF. One-year LTx-free
survival was significantly lower with NAC, particularly among those <2 years old. These results do not
support broad use of NAC in non-APAP PALF and emphasizes the importance of conducting con-
trolled pediatric drug trials, regardless of results in adults. (HEPATOLOGY 2013;57:1542-1549)
P
ediatric acute liver failure (PALF) is a rare and
devastating syndrome in which previously
healthy children rapidly lose hepatic function
due to a variety of causes and become critically ill
within days.1,2 Management is largely supportive
unless conditions that are amenable to directed ther-
apy, such as acute acetaminophen toxicity, herpes virus,
and potentially treatable causes such as Wilson’s disease
and autoimmune hepatitis are identified and treated.3,4
Early referral to a liver transplantation (LTx) center,
See Editorial on Page 1297
Abbreviations: A-CA, acetaminophen-cysteine adducts; ARDS, acute respiratory distress syndrome; CPS, cumulative percentage surviving; D5W, 5% dextrose in
water; DCC, Data Coordinating Center; EBV, Epstein-Barr virus; FiO2, fraction inspired oxygen; HE, hepatic encephalopathy; ICU, intensive care unit; IND,
Investigational New Drug; INR, international normalization ratio; LTx, liver transplantation; MOSF, multiorgan system failure; NAC, N-acetylcysteine; NIDDK,
National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; Non-APAP, nonacetaminophen acute liver failure; PALF,
pediatric acute liver failure; PALFSG, Pediatric Acute Liver Failure Study Group; PT, prothrombin time; SAE, serious adverse event.
From the 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 2Kings College, London, UK; 3Northwestern University, Evanston, IL; 4University of
Colorado SOM and Children’s Hospital Colorado, Boulder, CO; 5University of Texas Southwestern Medical Center, Dallas, TX; 6Birmingham Children’s Hospital,
Birmingham, UK; 7Baylor College of Medicine, Houston, TX; 8Cincinnati Children’s Hospital, Cincinnati, OH; 9Columbia University, New York, NY; 10Children’s
Hospital of Philadelphia, Philadelphia, PA; 11University of California-San Francisco, San Francisco, CA; 12University of Washington, Seattle, WA; 13Hospital for Sick
Children, Toronto, Canada; 14Indiana University, Indianapolis, IN; 15Mt. Sinai Medical Center, New York, NY; 16Washington University, St. Louis, MO;
17University of Michigan, Ann Arbor, MI; 18Johns Hopkins University, Baltimore, MD; 19Emory University, Atlanta, GA; 20Children’s Hospital of Boston, Boston, MA;
21National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD; 22Graduate School of Public Health, University of
Pittsburgh, Pittsburgh, PA.
Received March 16, 2012; accepted July 16, 2012.
1542
improvements in medical management, and LTx are
associated with improved survival in PALF.5 Long-
term outcomes following LTx for PALF are poor com-
pared to other indications for LTx,6,7 hence the need
to identify treatments that improve survival. N-acetyl-
cysteine (NAC), used for treating acute acetaminophen
(APAP) toxicity, has been used to treat non-APAP
PALF but has not been rigorously tested in a multi-
center placebo-controlled clinical trial in children.8,9
NAC replenishes mitochondrial and cytosolic gluta-
thione stores and is the treatment of choice for acute
APAP toxicity.10,11 Intravenous NAC became incorpo-
rated into the general management of acute liver fail-
ure in a number of sites in Europe and North America
following a small uncontrolled study suggesting
improved cardiovascular hemodynamics and oxygen
transport in both APAP and non-APAP liver failure in
adults.12 A retrospective single-site review in children
affirmed the view that NAC may provide benefit in
PALF.8 In a randomized trial of intravenous NAC versus
placebo in adults with non-APAP liver failure, NAC did
not improve survival at 21 days.13 However, an analysis
of the secondary outcomes revealed improved LTx-free
survival at 3 weeks for those with grade 1-2 hepatic
encephalopathy (HE). The primary objective of this
study was to determine if a continuous intravenous infu-
sion of NAC for up to 7 days would improve overall
survival compared to placebo 1 year following treatment
allocation in non-APAP PALF.
Patients and Methods
Study Oversight. This study was funded by the Di-
vision of Digestive Diseases and Nutrition within the
National Institute of Diabetes and Digestive and Kid-
ney (NIDDK) Diseases of the National Institutes of
Health (NIH) and was registered with www.Clinical-
Trials.gov (NCT00248625). Study design and manage-
ment of the NAC trial was accomplished by academic
clinical investigators and site coordinators associated
with the Pediatric Acute Liver Failure Study Group
(PALFSG). A Data and Safety Monitoring Board
(DSMB) consisting of experts in pediatric hepatology,
pediatric LTx, and statistical analysis was appointed by
the NIH/NIDDK and did not have any conflicts of in-
terest with members or institutions that constituted the
PALFSG or the suppliers of NAC. NAC was initially
provided by Apothecon/Geneva Pharmaceuticals
(Princeton, NJ), a division of Bristol Myers Squibb, and
after April 2003 was supplied by Cumberland Pharma-
ceuticals (Nashville, TN). The Investigational New
Drug application (IND) was held by the Principal Inves-
tigator for the trial (R.H.S.). The PALFSG consisted of
20 pediatric sites in North America and the United
Kingdom and a Data Coordinating Center (DCC).
Study Population. Eligible participants for the NAC
trial were drawn from a registry of children with PALF
established at PALFSG sites. Each site was a pediatric
liver transplantation center and no donor organs were
obtained from executed prisoners or other institutional-
ized persons. The goal of the registry was to collect
detailed information from children with PALF. Entry cri-
teria for the PALF registry included children who were
under the age of 18 years, informed consent and assent
when appropriate, absence of a known chronic liver dis-
ease, biochemical evidence of acute liver injury, and a
liver-based coagulopathy, not corrected by parenteral vita-
min K. Clinical evidence of HE was required if the pro-
thrombin time (PT) was between 15-19.9 seconds or the
International Normalization Ratio (INR) was between
1.5-1.9. HE was not required for a PT of at least 20 sec-
onds or an INR at least 2.0, given the challenges of
assessing clinical HE in infants and children. Detailed
clinical and biochemical information was collected pro-
spectively for up to 7 days following enrollment.2,14,15
From February 2001 through September 2009, 635
children enrolled in the PALF registry after site-specific
Institutional Review Board (IRB) approvals for the
NAC trial were obtained. Eligibility criteria for the
NAC trial included enrollment in the PALFSG registry
and completion of a separate informed consent for the
NAC study from a parent or guardian and an informed
assent from the patients who were 14-17 years of age,
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developmentally able to sign his or her name, and were
without clinical HE.
Exclusion criteria included known acute acetamino-
phen toxicity, prior exposure to N-acetylcysteine dur-
ing the course of the presenting illness, pregnancy,
malignancy, sepsis, signs of cerebral herniation, being
on a liver support device, intractable hypotension
defined as systolic blood pressure less than 85 mmHg or
hypotension that required treatment with inotropic
drugs, other than renal dosing dopamine, and other
issues that in an investigator’s opinion made a potential
participant unsuitable for the study. We defined ‘‘sepsis’’
in the manual of operations as a having bacteremia and/
or a temperature of 39.5C at the time of enrollment. If
the patient was known to have a specific infection or if,
in the opinion of the site principal investigator, the
patient was suspected of having sepsis, prior to enroll-
ment into the NAC trial, they were excluded.
Study Design. The NAC study was doubly masked.
Eligible children were adaptively allocated within strata
defined by age (less than 2 years of age or at least 2
years old) and HE (grade 0-1 or 2-4) to receive NAC
(150 mg/kg/d) in 5% dextrose (D5W) and water or
placebo consisting of an equal volume of D5W alone.
Volumes were adjusted for small children. Study medica-
tions were infused over 24 hours for up to 7 consecutive
days in a dedicated line without other medications. Treat-
ment was stopped earlier than 7 days in the case of hospi-
tal discharge, LTx, or death within 7 days of randomiza-
tion. Although multiple different dosing regimens have
been used in previous studies,8,12,13,16,17 a recent retro-
spective study8 utilized a continuous infusion to support
the evolving and dynamic nature of ALF in children.
Clinical parameters including vital signs, diagnostic
and clinical laboratory tests, need for ventilatory, renal or
other supportive measures, coma, and adverse events were
recorded. With the exception of study medication,
patient management conformed to the standard of care at
each participating site, including decisions related to LTx.
The primary outcome was 1-year survival following
treatment allocation. Secondary outcomes included LTx,
survival without LTx, lengths of intensive care unit (ICU)
and hospital stay, maximum degree of HE, and number
of organ systems failing. Organ systems and definitions of
failure were: (1) cardiovascular failure: the patient requires
treatment with inotropic drugs such as norepinephrine,
epinephrine, or dopamine (the latter >5 lg/kg/min) at a
time prior to the terminal 24 hours before death to at-
tribute cardiovascular failure to liver failure and not ter-
minal events; (2) renal failure: serum creatinine greater
than 2 times the upper limit of normal for age and urine
output less than 0.5 cc/kg/hour; (3) intracranial hyperten-
sion: intracranial pressure >25 mmHg if ICP monitored
or clinical signs such as decerebrate posturing or abnor-
mal pupillary reflexes; (4) pulmonary failure: need for me-
chanical ventilation for HE or respiratory failure, defined
as an inspired oxygen fraction (FiO2) above 0.40, the first
12 hours after intubation and the terminal 12 hours before
death excluded; and (5) infection: defined as identification,
by culture, serologies, polymerase chain reaction (PCR) or
immunofluorescence, of a specific microorganism or virus
present in blood, tracheal aspirate, urine, intravenous cath-
eter, wound, liver tissue, stool, naso-pharynx, cerebral spi-
nal fluid, bone marrow, or ascites.
Statistical Analysis. Differences in baseline character-
istics of participants in each treatment arm were tested
using Pearson’s chi-square test or Fisher’s exact test for cat-
egorical variables and the Wilcoxon rank sum test for
continuous variables. Product-limit estimates were used
to obtain the cumulative percentages of participants sur-
viving 1 year following randomization and the percen-
tages of participants surviving 1 year following random-
ization with their native liver. A log-rank test was used to
assess statistical significance of the difference in survival
curves. The proportional hazards model18 was used to
estimate the relative risk for both outcomes adjusting for
age (less than 2 years, at least 2 years) and HE grade at
randomization (0-1, 2-4), which were used as strata in
the minimization scheme. Differences between treatment
arms for length of hospital stay and length of ICU stay
were tested for statistical significance using the Kruskall-
Wallis test and the Cochran-Armitage test for trend,
respectively. Tests of ordinal measures were used to ena-
ble us to account for deaths or transplantations that
occurred prior to discharge from the hospital or ICU,
respectively. Transplantations that occurred prior to dis-
charge were assigned a value greater than the maximum
stay and deaths occurring prior to discharge were
assigned a value greater than transplantation. Pearson’s
chi-square test or Fisher’s exact test were used to test
the null hypothesis of no difference in the proportion
of participants in each treatment arm who had each
organ system fail, and the Cochran-Armitage test for
trend was used to test for treatment arm differences in
the number of organ systems failing and for maximum
grade of HE. Due to two interim analyses, the P-value
for statistical significance of each outcome was 0.0490,
overall and in subgroups. For all other comparisons, P
< 0.05 was used to determine statistical significance.19
Results
Baseline Characteristics. Of the 607 participants in
the PALF registry eligible for screening for the NAC
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study, 336 were ineligible (Fig. 1). Ineligibility criteria
remained constant throughout the study, but reasons
for ineligibility were not recorded on the initial case
report form for 165 participants and are shown as
‘‘reason unknown.’’ Of the remaining 171, reasons for
ineligibility were recorded. In addition to those who
failed to meet inclusion criteria, or who met at least
one exclusion criterion, five died in the interval between
entry into the PALF longitudinal study and the 24
hours allotted to enroll into the NAC trial. Another 13
were excluded for other reasons: seven had preexisting
conditions that, in the opinion of the investigator,
excluded them from the trial, two were demonstrating
clinical recovery from PALF, two were excluded because
they presented when the trial was briefly suspended to
ensure all sites were in agreement with the statistical
analyses plan, one patient was not able to be random-
ized due to technical difficulties with computer entry,
and in for one patient liver transplantation was immi-
nent. Of the 271 potentially eligible, consent was not
obtained from 87, leaving 184 participants with 92 allo-
cated to each treatment. Two participants withdrew
from the placebo arm and no one withdrew from the
NAC arm. One participant was randomized to placebo
but received NAC. One randomized participant in the
placebo arm had APAP toxicity that was determined
during the hospitalization but after treatment allocation;
this patient exited the study and was treated with NAC
clinically. One patient was found to have biliary atresia
after treatment allocation. All of these participants were
analyzed in the treatment arm to which they were
assigned (intention-to-treat analysis).
The two treatment groups did not differ signifi-
cantly with respect to age, gender, race, coma grade,
biochemical measures of liver injury, and time from
admission to hospital until enrollment into the trial
(Table 1). The distribution of final diagnoses did not
differ significantly between the two groups (P ¼ 0.09)
(Table 2). Although an indeterminate diagnosis was
the most common, other diagnoses such as infection
and autoimmune disease were all comparably common
in the two treatment groups. Metabolic disease was
more common in the NAC arm (13 NAC versus five
placebo) with Wilson’s disease (seven NAC versus three
placebo) being more common in the NAC arm than
the placebo arm. ‘‘Other’’ diagnoses were more com-
mon in the placebo arm (seven NAC versus 17 pla-
cebo) with hemophagocytic syndrome (none NAC ver-
sus four placebo) and drug-induced hepatitis (one
NAC versus three placebo) showing the greatest differ-
ences within the ‘‘other’’ rare diagnostic category.
Study Outcomes. For the primary outcome (Fig. 2),
there was no significant difference (P ¼ 0.19) in the sur-
vival 1 year following randomization between those
receiving NAC (73%) compared to placebo (82%).
There was no significant difference (P ¼ 0.37) in
Fig. 1. Enrollment in the NAC trial.
Between June 2003 and September
2009, 607 patients enrolled in the
PALF longitudinal study were screened
following site-specific IRB approval for
the NAC protocol; 336 were ineligible.
Of the 271 patients eligible for enroll-
ment, 87 refused consent, leaving 184
enrolled in the NAC trial; there were 92
patient in each arm. Only two patients
withdrew following enrollment, and they
were both in the placebo arm.
Table 1. Baseline Characteristics
NAC N ¼ 92 Placebo N ¼ 92 P
Male, N (%) 47 (51.1) 54 (58.7) 0.30
Not Hispanic or Latino, N (%) 75 (81.5) 66 (71.7) 0.12
Caucasian 68 (73.9) 65 (70.7) 0.62
Age (years)
Median (25%, 75%) 3.7 (0.8, 10.5) 4.5 (1.0, 9.5) 0.53
< 2, N (%) 33 (35.9) 29 (31.5) 0.53
Coma grade at randomization, N (%) 0.62
0 – 1 65 (70.7) 68 (73.9)
2 – 4 27 (29.3) 24 (26.1)
Initial admission to study
enrollment (days)
0.47
Median (25%, 75%) 3 (1, 7) 3 (1, 5)
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survival between the 65 children with HE grade 0-1 who
received NAC and the 68 who received placebo. Stratifi-
cation of results by age above and below 2 years, by HE
grade 0-1 and grade 2-4, and the combinations of age
and HE grade did not reveal significant treatment differ-
ences within any of the subgroups (Supporting Table 1).
Of the secondary outcomes that were examined, the 1-
year LTx-free survival (Fig. 3) was significantly (P ¼ 0.03)
lower in children who received NAC (35%) compared to
placebo (53%). Children less than 2 years of age were sig-
nificantly (P ¼ 0.03) less likely to survive with their native
liver at 1 year if they received NAC (n ¼ 34, LTx-free sur-
vival ¼ 29%) than if they received placebo (n ¼ 31, LTx-
free survival ¼ 58%). Despite a large difference in the
point estimate, children less than 2 years of age with HE
grade of 0-1 did not have a significantly lower LTx-free
survival (P ¼ 0.0493) if they received NAC (n ¼ 20; LTx-
free survival ¼ 25%) than did children in the same age
and HE grade categories who received placebo (n ¼ 20;
LTx-free survival ¼ 60%). There were no significant dif-
ferences between the treatment groups with respect to
length of ICU or hospital stay, type or number of organ
systems failing, or maximum grade of HE recorded follow-
ing treatment allocation.
Posttransplant survival was not significantly different
between the two groups. Duration of posttransplant
follow-up varied depending on the timing of LTx after
randomization. The cumulative probability of survival
9 months (274 days) postrandomization was 0.88 in
the NAC arm and 0.84 in the placebo arm (P ¼
0.59). This is due to five post-LTx deaths among 41
in the NAC arm who underwent transplantation, and
five deaths in the placebo arm among the 32 in the
placebo arm who underwent transplantation.
Acetaminophen Adducts. Eighty-four participants
had a sufficient amount of serum collected on day 1
or 2 following enrollment to be analyzed by a sensitive
and specific serum assay for acetaminophen-cysteine





Indeterminate 55 (59.8) 54 (58.7)
Autoimmune 8 (8.7) 11 (12.0)
Infection 9 (9.8) 6 (6.5)
Metabolic 13 (14.1) 5 (5.4)




Glycosylation defect 1 0
Niemann-Pick type C 1 0
Other 7 (7.6) 16 (17.4)
Hemophagocytic syndrome 0 4
Drug-induced hepatitis 0 3
Neonatal iron storage disease 1 2
Acetaminophen overdose 0 1
Extra-hepatic biliary atresia 0 1
Hemagioendothelioma 0 1
Intraventricular hemorrhage 1 0
Methanol 0 1
Systemic lupus erythematosis 0 1
Drug-induced and sepsis 1 0
Influenza A 1 0
Influenza B 1 0
Sepsis 0 1
EBV þ hemophagocytic syndrome 0 1
Shock þ adenovirus infection 1 0
Shock ischemia 1 0
P-value ¼ 0.09 from chi-square test.
Fig. 2. Primary outcome: 1 year survival. Product-limit estimates
were used to obtain the cumulative percentages of participants surviv-
ing 1 year following randomization. A log-rank test was used to assess
statistical significance of the difference in survival curves. The cumula-
tive percentage of children who were alive 1 year following randomiza-
tion to NAC (dashed line) or placebo (solid line) is depicted. The
percent surviving 1 year was higher in patients receiving placebo at
82% than NAC at 73%, but the differences were not significant with a
P-value of 0.19.
Fig. 3. Product-limit estimates were used to obtain the cumulative
percentages of participants with 1-year transplantation-free survival. A
log-rank test was used to assess statistical significance of the difference
in survival curves. The cumulative percentage of children with liver trans-
plantation-free survival 1 year following randomization to NAC (dashed
line) or placebo (solid line) is depicted. The cumulative percentage of
patients with liver transplantation-free survival was 53% when given pla-
cebo versus 35% when given NAC, with a P-value of 0.03.
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adducts (A-CA).20,21 Testing for A-CA was performed
for research purposes; results were neither available,
nor used, for clinical purposes. The final diagnosis was
provided by the site principal investigator without
knowledge of the results of the A-CA. The presence of
A-CA is a biomarker for patients with acetaminophen-
related liver injury. There were no statistically significant
differences in the characteristics (Supporting Table 2) or
outcomes (Supporting Table 3) examined of the 84 who
were tested for A-CA compared to the other 100 in the
trial who did have sera available for testing. Of those who
were tested, 9/84 (11%) tested positive for A-CA, with
three of those having positive A-CA randomized to NAC
and the other six randomized to placebo; all survived 1
year after randomization; in the NAC arm, two under-
went LTx whereas none of the six in the placebo arm
underwent LTx. Final diagnoses of the A-CA-positive
patients were three indeterminate cases for those random-
ized to NAC and three indeterminate, one APAP, one vi-
ral hepatitis, and one sepsis randomized to placebo. The
patient with the final diagnosis of APAP was determined
during the hospitalization when a participant who ini-
tially denied APAP exposure subsequently gave a positive
history. This participant was given NAC clinically when
the history became known and exited the study.
Safety. At least one adverse event was reported for
19 participants given NAC (21 events) and 16 given pla-
cebo (17 events). The most common adverse event
reported was infection (11 in the NAC arm versus eight in
the placebo arm). Other adverse events reported among
those given NAC versus those given placebo were rash
(four versus two), bronchospasm (one versus none), and
arrhythmia (one versus four). There were no significant
differences in adverse event rates between the treatment
arms. The other events listed for participants in the NAC
arm were aspiration, dilated and fixed pupils, hyperten-
sion, and pleural effusion. One participant each in the pla-
cebo arm had sleepiness, bradycardia, and high fever.
There were five participants in the NAC arm with seri-
ous adverse events (SAEs); four had a single SAE (respira-
tory distress, Staphylococcus aureus bacteremia, bradycar-
diac episode, hypoglycemia) and the other participant
had three SAEs (aplastic anemia; Epstein-Barr virus
[EBV] posttransplantation lymphoproliferative disease;
and fever, chills, and sinusitis). Four participants in the
placebo arm had a single SAE (small intestine ulcerations,
fever, sensorineural hearing loss, and bigeminy).
Discussion
NAC, given as a continuous intravenous infusion at
a dose of 150 mg/kg/d for up to 7 days to children
with non-APAP acute liver failure, did not achieve the
primary outcome, which was to improve survival 1
year following the infusion compared to placebo. Nor
did NAC improve 1-year survival in any of the sub-
groups defined by stratifying variables for the minimi-
zation scheme (age group, HE grade). Interestingly,
analysis of secondary outcomes revealed that survival
at 1 year with their native liver was significantly lower
in children treated with NAC compared to placebo. In
addition, we found that children with minimal HE of
grade 0-1 did not benefit from the NAC infusion.
This finding differs from secondary outcomes analysis
of adults, which found NAC to benefit those with
grade 0-II HE.13 Adverse events were similar between
NAC and placebo arms in our study. The striking dif-
ference between the effects of NAC in children as
compared to adult patients is likely related to a num-
ber of factors that include differences in etiology,
underlying pathophysiology, and age.
Acute liver failure in children is a heterogeneous,
dynamic clinical entity with etiologies that differ from
adults.4,22 Although etiologic categories of nonacetami-
nophen acute liver failure in children are similar to
adults and include, metabolic, infectious, and
immune-mediated conditions, medications, and other
toxins as well as an indeterminate group, the propor-
tion of children within those categories differs substan-
tially from adults. Although an indeterminate diagnosis
accounted for 24% in the adult study,13 54% of the
pediatric cases had such a diagnosis. Similar propor-
tions were noted in the larger cohort of PALF partici-
pants not specifically included in this clinical trial.2,23
A portion of the pediatric indeterminate group likely
constitutes an evaluation interrupted by death, LTx, or
clinical improvement. In addition, the indeterminate
cohort may include unexpected acetaminophen toxic-
ity,21 a novel or unrecognized virus, metabolic or xeno-
biotic injury. Undiagnosed immune dysregulation may
also result in ALF.24
The presence of A-CA has been associated with
known and occult acetaminophen-related liver dis-
ease.21,25 The percent of patients with a positive A-CA
in the NAC trial is similar to previous studies in chil-
dren.21 Although the numbers are very small, all of the
A-CA-positive patients randomized to placebo survived
at least 1 year without LTx. Reasons for this finding
might include APAP toxicity that was not the primary
driver of liver failure or, perhaps, adducts were generated
when the injured liver was exposed to APAP.
In previous studies, NAC was evaluated for the
treatment of multiorgan system failure (MOSF)
including acute respiratory distress syndrome (ARDS)
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and sepsis,26 and was found to improve pulmonary
compliance and oxygen consumption with variable
results on overall patient survival.12,16,17 NAC sup-
presses the production of tumor necrosis factor alpha
(TNF-a) in vitro27 and improves survival and lung
function in pigs with endotoxin-induced ARDS.28 As
clinical features of ALF overlap with those seen in
MOSF syndromes, we hypothesized that the nonspe-
cific beneficial effects of NAC in MOSF might well
apply to ALF. Unfortunately, with respect to 1-year
survival, NAC did not provide the anticipated benefit.
The observation that NAC failed to improve and
possibly worsened the likelihood of LTx-free survival
at 1 year suggests pathobiological mechanisms of non-
APAP acute liver failure may differ between children
and adults. These findings provide an opportunity to
identify novel mechanisms of hepatocellular injury in
PALF such as immune dysregulation29 or an altered
inflammatory response30 and investigate targeted treat-
ment strategies in children with acute liver failure.
Hypotheses can be generated to help explain our find-
ings. One hypothesis is that immune or inflammatory
dysregulation drives liver injury for many in the indeter-
minate cohort. Although little is known of the ontogeny
of intrahepatic immune responses, evidence suggests sys-
temic inflammatory responses to trauma differ signifi-
cantly between adults and children.31 Inflammation is a
complex and dynamic process that encompasses both
injury, healing, and regeneration through proinflamma-
tory and antiinflammatory responses.30 A well-regulated
inflammatory response is necessary for proper healing
and regeneration.32 Should proinflammatory signals
that initiate healing and regenerative responses be
blunted at a critical time, an imbalance favoring inflam-
mation may develop. Whether NAC, which serves as an
antioxidant33 and can alter the secretion of a variety of
chemokines,34 could interrupt healing responses is not
known. A second hypothesis is that prolonged treatment
with NAC might suppress the hepatic regenerative
response to injury, as was recently reported in a murine
model of APAP-induced liver injury.35
Other variables that may have impacted our findings
include differences in diagnosis between treatment
arms, dosing regimen, and the extended enrollment
period. Children with mitochondrial disease suffer
from a systemic condition associated with late mortal-
ity that is currently without a directed therapy.
Although antioxidant therapy with NAC may have
theoretical benefit for mitochondrial injury, the oppo-
site might also be true.36 Treatment of drug-induced
liver injury is generally limited to withdrawal of the
offending medication. A recent study reported that
NAC might provide benefit independent of glutathi-
one repletion in a murine model of lasix-induced liver
injury, raising the possibility that NAC might also
have such effects in human drug-induced liver.37
Although uneven distribution of these rare conditions
may have a theoretical impact on outcomes for indi-
viduals, the small numbers are unlikely to be a major
factor in the outcome of the trial.
The NAC dosing regimen of 150 mg/kg/d for no
more than 7 days fits within other adult and pediatric
dosing regimens that have ranged from 288 mg/kg/d
for up to 5 days with MOSF16 to 100 mg/kg/d for a
median of 5 days (range 1-77) in ALF. The study du-
ration, requiring 9 years to recruit the number of
participants required by the study design, speaks to the
challenges of studying a rare, acute, severe condition
such as PALF. Despite the prolonged period, we have
no evidence that significant changes in management or
liver transplant decisions occurred during the course of
the study that would have impacted the outcome.
In summary, NAC did not improve 1-year survival
in children with non-APAP acute liver failure. One-
year LTx-free survival was significantly lower in the
NAC-treated group, especially among children less
than 2 years of age with HE grade 0-1. Although the
difference in outcome by treatment arm was large in
that small group, the interim analyses and small sam-
ple size reduced substantially the statistical power to
find a large difference to be statistically significant.
This study does not support the broad use of NAC in
non-APAP PALF and it emphasizes the importance of
conducting prospective pediatric drug trials, regardless
of results in adults.
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